Our Bureau

Mumbai, July 26

Lupin Ltd has received regulatory approval to conduct the second phase of human-trials on its prospective drug targeting psoriasis, a skin-related condition.

The Drug Controller General of India (DCGI) has given its approval to conduct Phase-II clinical trials for its psoriasis pure compound LL-4218 (Desoside-P), a note from Lupin said.

In Phase II trials, the prospective medicine is targeted at a sample-size of 100-500 human subjects infected with the disease. Lupin expects to begin clinical trials at about six centres immediately, a note from the company said. The total market for psoriasis is estimated to be in excess of $2 billion. The company also has three other new chemical entities in various stages of clinical trials, the note added.

(This article was published in the Business Line print edition dated July 27, 2006)
XThese are links to The Hindu Business Line suggested by Outbrain, which may or may not be relevant to the other content on this page. You can read Outbrain's privacy and cookie policy here.